

This material is an English translation of the press release announced on July 26, 2016 in Japanese, and the Japanese release is given priority about the content and the interpretation.

July 26, 2016

**Notification of the Noven Pharmaceuticals, Inc. assigns rights for
Brisdelle[®] (Paroxetine) Capsules and Pexeva[®] (Paroxetine Mesylate) Tablets**

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga prefecture, Japan; Chairman and CEO: Hirotaka Nakatomi, hereinafter referred to as Hisamitsu) hereby announces that its wholly owned subsidiary in the United States, Noven Pharmaceuticals, Inc. (Head Office: Miami, Florida, hereinafter referred to as “Noven”) has reached agreement with Sebel International Limited (hereinafter referred to as “Sebel”) to assign rights of approval for manufacture, commercialization and associated intellectual property for Brisdelle[®] (Paroxetine) Capsules, 7.5 mg and Pexeva[®] (Paroxetine Mesylate) Tablets to Sebel.

The sales for Brisdelle[®] and Pexeva[®] are approximately \$23 Million (FY02/2016 results). Financial impact from this transaction is not expected to be material. There are no changes to the earnings forecast for FY02/2017.